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The interest in genetic manipulations of PPARs is as old as their discovery as receptors of ligands with beneﬁcial clinical activities.
Considering the eﬀects of PPAR ligands on critical aspects of systemic physiology, including obesity, lipid metabolism, insulin
resistance, and diabetes, gene knockout (KO) in mice is the ideal platform for both hypothesis testing and discovery of new PPAR
functions in vivo. With the fervent pursuit of the magic bullet to eradicate the obesity epidemic, special emphasis has been placed
on the impacts of PPARs on obesity and its associated diseases. As detailed in this review, understanding how PPARs regulate
gene expression and basic metabolic pathways is a necessary intermediate en route to deciphering their eﬀects on obesity. Over a
decade and dozens of genetic modiﬁcations of PPARs into this eﬀort, valuable lessons have been learned, but we are left with more
questions to be answered. These lessons and future prospects are the subject of this review.
Copyright © 2007 Y. Barak and S. Kim.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. PPARα
The only PPAR faithful to its acronym, PPARα, is the nu-
clear receptor of peroxisome proliferators—a diverse group
of compounds, which in addition to toxic and carcino-
genic chemicals include the lipid-lowering ﬁbrate drugs [1].
PPARα is expressed in active metabolic tissues, including
liver, heart, brown fat, and skeletal muscle, where it regu-
lates genes that catalyze fatty acid (FA) catabolism [1, 2].
By 1995, mice homozygous for a Ppara- n u l la l l e l ew e r eg e n -
erated and found to be viable, healthy, fertile, and devoid
of gross phenotypic defects under standard husbandry [3].
However, these mice could mount neither the hepatic re-
sponse to peroxisome proliferators nor the induction of
lipid-metabolizing enzymes by ﬁbrates [3, 4]. These results
conﬁrmedthenullnatureofthisallele,andobviatedtheneed
for alternative null conﬁgurations; consequently, this strain
has become the exclusive animal model for studies of PPARα
deﬁciency to date. These studies are summarized below.
1.1. PparaKOandobesity
EarlystudiesofPpara-nullmicereportedhepatosteatosisand
elevated levels of circulating triglycerides (TG) and choles-
terol, as well as a signiﬁcant increase in gonadal fat pad mass
[5–8]. The integral role of PPARα in body fat mass deter-
mination is further cemented by the demonstration that the
KO mice fail to decrease adipose tissue weight in response
to hyperleptinemia [9]. However, the contribution of PPARα
to total body weight is ambiguous, with conﬂicting reports
of substantial age-related obesity [6, 7] versus no signiﬁ-
cant body weight eﬀects in congenic 129/SvJae or C57BL/6N
Ppara−/− mice [8]. The discrepant outcomes of these studies
have been attributed to subtle experimental variations in the
genetic background and chow composition, and suggest that
the contribution of PPARα to obesity is strongly inﬂuenced
by genomic and environmental contexts.
1.2. PparaKOandfasting
The relatively minor phenotype of Ppara-null mice under
standard husbandry conditions is consistent with a contin-
gency function that comes into play under metabolic duress.
Accordingly, multiple studies addressed the ability of Ppara-
null to cope with dietary challenges. The most informative
manipulation has been fasting, during which PPARα de-
ﬁciency was shown to cause excessive surge in circulating
FA levels, rapid hepatic and cardiac lipid accumulation, ab-
sentketogenicresponse,profoundhypoglycemiaandhepatic
glycogen depletion [10–13]. These anomalies are thought to2 PPAR Research
arise from failure of the mutant livers to catabolize adipose
tissue-derived FA, which on the one hand impairs gluco-
neogenesis at both enzyme activity and substrate levels, and
on the other hand leads to morbid accumulation of non-
metabolized lipids [14, 15]. PPARα is similarly critical for
cardiac lipid oxidation, which is the main energy source for
the heart during fasting and exercise; reviewed in [16]. Both
constitutive and inducible expression of PPARα target genes
are blunted in Ppara-null hearts, which exhibit abnormal
TG accumulation during fasting and progressive deteriora-
tion of myoﬁbrillar and mitochondrial integrity upon aging
[10, 17]. The crucial importance of PPARα-mediated hep-
atic and cardiac lipid catabolism, regardless of fasting, is also
evident in the severe hypoglycemia and staggering lipid ac-
cumulation in livers and hearts of Ppara-null mice follow-
ing pharmacological inhibition of FA ﬂux [18]. Interestingly,
female and estrogen-treated male Ppara-null mice are sig-
niﬁcantly protected against this lethal combination of tissue
hyperlipidemia and systemic hypoglycemia, implying an al-
ternative, estrogen-dependent lipid utilization pathway [18].
While proper cardiac metabolism is disrupted in the absence
ofPPARα,dosageandtemporalregulationofthereceptorare
critical, and its constitutive transgenic overexpression in car-
diacmuscleviatheαmyosinheavychain(MHC)promoteris
detrimental [19]. Hearts of MHC-Ppara transgenic mice ex-
hibit a faithful phenocopy of diabetic cardiomyopathy, with
increasedlipidoxidation,areciprocaldecreaseinglucoseuti-
lization, and symptoms of ventricular hypertrophy [19].
1.3. PparaKOinhigh-fatandcholesterol-richdiets
The role of PPARα in the physiological outcomes of high
fat diet (HFD) is not as clear as its role in fasting physiol-
ogy. Ppara-null mice are as susceptible as wt mice to HFD-
induced weight gain and hepatic TG accumulation, but are
protected from glucocorticoid-induced hypertension [20–
22].Bluntedhyperinsulinemiaandimprovedglucoseandin-
sulin tolerance following 2-hour fasting suggested initially
that HFD-fed Ppara-null mice are protected from insulin re-
sistance (IR) as a result of either reduced hepatic glucose
production or increased peripheral insulin sensitivity [20].
However, this report has been contested by a study that
found little diﬀerence in hyperinsulinemia and peripheral
glucose uptake during euglycemic clamp of HFD-fed wt ver-
sus Ppara-null mice in the nonfasted state [23]. This con-
tradictory result raised the concern that the improved in-
sulin and glucose tolerance of HFD-fed Ppara-null mice in
the earlier studies reﬂects no more than their established hy-
poglycemicresponsetothefastingregimenthatprecededthe
assays; studies that bypass this conceptual hurdle will be re-
quired to reevaluate the role of PPARα in the aftermath of
HFD. Because the consequences of PPARα deﬁciency also
include a constitutive increase in circulating cholesterol, it
is equally important to test the eﬀects of a cholesterol-rich
diet in Ppara-null mice. Surprisingly, addition of 2% choles-
terol to the chow caused fat pad weight reduction and in-
creased de novo lipogenesis in Ppara-null mice, indicating
thatthereceptorparticipatesinbasalandfeedback-regulated
cholesterol and triacylglycerol homeostasis in adipose tissue
[24]. These activities impinge directly on the contribution of
PPARα to obesity.
1.4. EffectsofPparaKOonothertissues
Unlike the eﬀect of PPARα on cardiac muscle, PPARα de-
ﬁciency had no signiﬁcant eﬀect on the responses of skele-
tal muscle to either fasting or heavy exercise, perhaps due to
compensation by redundant functions of PPARδ [25]. How-
ever, transgenic overexpression of PPARα in skeletal mus-
cle, using the muscle creatine kinase (MCK) promoter, pro-
tected mice from HFD-induced obesity, albeit at the expense
of glucose intolerance and insulin resistance [26]. The pro-
posed mechanism entails reduced insulin-stimulated glucose
uptake due to repression of AMP-activated protein kinase-
dependent glucose transporter gene expression by oxidized
FA. The hepatocentric view of systemic PPARα eﬀects is
moderated by a recent report of increased peripheral glucose
utilization in fasted Ppara-null mice, which was refractory to
adenovirus-mediated reconstitution of hepatic PPARα [27].
Moreover, direct injection of a PPARα agonist into the lateral
ventricle of wt mice signiﬁcantly reduced whole body glu-
cose utilization, suggesting that PPARα also functions cen-
trally [27]. Tissue-speciﬁc Ppara-null mice, which have yet
to be generated, would be an ideal platform to validate and
further explore these intricate mechanisms of PPARα action.
2. A PANOPLY OF PPARγ KNOCKOUTS
Without detracting from the importance of PPARα and
PPARδ (see below for PPARδ), the deﬁning moment in the
explosive growth of the PPAR ﬁeld has been the identiﬁca-
tion of PPARγ as the high-aﬃnity receptor of the insulin-
sensitizing thiazolidinedione (TZD) drugs [28, 29]. The piv-
otal role of PPARγ in the adipocyte life cycle [30–34], com-
bined with the blockbuster success of its TZD ligands in
treating type II diabetes [35, 36], generated widespread en-
thusiasm for the prospect of solving the causal relation-
ship between obesity and diabetes through PPARγ research.
The use of gene knockout in mice presented the most log-
ical investigative approach, leading to the generation of a
dazzling array of mouse strains with genetic modiﬁcations
of Pparg.T h i sv o l u m eo fe ﬀort reﬂects not only the im-
mense biomedical signiﬁcance of the gene, but also the com-
plexity of the genetic data, which had encumbered imme-
diate, straightforward understanding of PPARγ function in
vivo and had spawned numerous alternative hypotheses. The
myriad Pparg KOstrains,andtheresultsoftheiranalyses,are
summarized below.
Constitutive Pparg deﬁciency cannot be studied in adult
mice due to the essential role of PPARγ in placental de-
velopment, which abolishes survival beyond mid-gestation
[34]. However, aggregation with tetraploid wt embryos pro-
vided Pparg-null embryos with wt placentas and rescued
t h e mt ot e r m[ 34]. In these chimeras, Pparg-null cells com-
mitted to the adipocyte lineage, but failed to proliferate and
diﬀerentiate into bona ﬁde adipocytes, and a chimeric pup
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of adipose tissue [34]. This eﬀort proved the essential role of
PPARγ in early adipogenesis in vivo, but unfortunately, peri-
natallethalityprecludedstudiesofthisPparg-nullconﬁgura-
tionbeyondbirth.ThecurrentavailabilityofﬂoxedPparg al-
leles (see below) and epiblast-speciﬁc Cre-expressing mouse
strains [37, 38] should revitalize this conﬁguration by facili-
tating higher throughput generation of Pparg-null mice sup-
ported by wt placentas. Studies in progress in our lab with
standard wt/Pparg-null chimeras, in which diploid host-
derived wt cells coexist with Pparg-null ES-derived cells,
conﬁrmed the formation and subsequent arrest of Pparg-
null adipose tissue primordia. However, here wt cells inﬁl-
trated the stagnant Pparg-null primordia and repopulated
them through a previously unknown developmental feed-
back mechanism (S. Kim and Y. Barak, unpublished). Con-
sequently, post-term wt/Pparg-null chimeras invariably pos-
sess only wt adipose tissue, in contrast to the random contri-
bution of wt and Pparg-null cells to other tissues [31].
2.1. Pparg+/−mice
With bona ﬁde adult Pparg-null mice unavailable, investiga-
tors initially turned to Pparg-haploinsuﬃcient mice to ex-
plore the eﬀects of reduced PPARγ dosage. As expected, adi-
posity of Pparg+/− mice was reduced, supporting the asser-
tion that PPARγ contributes quantitatively to adipose mass
[39]. However, contrary to the expectation that reduced lev-
els of the TZD receptor will cause a parallel reduction in in-
sulin sensitivity, Pparg+/− mice were more insulin-sensitive
than wt controls when challenged by either HFD or aging
[39–41]. This confounding observation conﬂicts with the
monochromaticviewofPPARγ asabeneﬁcialTZD-activated
insulin sensitizer and raises the counterintuitive notion that
it has pathogenic activities. While the nature of these adverse
propertiesofthereceptorisunclear,onepotentialexampleof
a latent pathogenic eﬀect is the positive relationship between
PPARγ dosage and adipose tissue mass, which might come
into play under conditions of nutritional aﬄuence. However,
excessive reduction of PPARγ activity by treating haploinsuf-
ﬁcient mice with a PPARγ antagonist reversed the tide and
resulted in lipodystrophy and IR [42, 43].
2.2. Tissue-speciﬁcPpargKOs
Tissue-speciﬁc Pparg KOs were subsequently developed by
s e v e r a lg r o u p su s i n gCre-loxP methodology, with the vision
of both bypassing the embryonic lethality of constitutive
Pparg deﬁciency and resolving the physiological functions
of PPARγ one tissue at a time [32, 44, 45]. Pparg has since
been deleted in a substantial number of cell types, of which
the most pertinent to this review are adipocytes, myocytes,
and hepatocytes, and from a broader metabolic disease per-
spectivealsomacrophages,pancreaticβ-cells,renalcollecting
duct epithelia, and endothelial cells (referenced below).
2.2.1. Adipocyte-speciﬁcPpargKO
The abundant expression of PPARγ in adipocytes indicates
that its important functions in these cells extend beyond
its indispensability for their formation. Moreover, the asso-
ciation between obesity as well as type II diabetes and the
antidiabetic eﬀect of TZDs fuel the hypothesis that PPARγ
activity in adipocytes is a key to systemic insulin sensitiv-
ity. A mouse whose adipocytes lack PPARγ would provide
the ultimate test for this idea. Generation of such a model
was attempted using an adipocyte-speciﬁc Fabp4(aP2)-CRE
transgene.While,asmentionedearlier,PPARγ isessentialfor
adipocyte diﬀerentiation, the Fabp4 promoter is activated af-
ter completion of adipogenesis, and thus allows the PPARγ-
dependent formation of adipocytes prior to Pparg deletion
[32, 45]. Contrary to a widespread, unsubstantiated con-
cern, the Fabp4 promoter does not drive transgene expres-
sion in macrophages or other major metabolic tissues [32],
and therefore the phenotype of these mice is not muddled by
gene deletion in nonadipocyte cell types. Adipocyte-speciﬁc
Pparg-null mice exhibited rapid loss of brown adipose tissue
(BAT)andsubcutaneousfat[32,45].Astonishingly,however,
white adipose tissue (WAT) retained normal mass through-
out a substantial stretch of adulthood [32]. This retention
occurred despite substantial cell death and extensive ﬁbrosis
and inﬂammatory inﬁltration, and resulted from both overt
hypertrophy of surviving adipocytes and adipocyte regener-
ation [32, 45].
The tight dependence of adipocytes on PPARγ for sur-
vival and the interpretation that adipocyte regeneration mit-
igates lipodystrophy were unequivocally proven by studies
of mice with tamoxifen-inducible adipocyte Pparg KO [33].
These mice carry a loxP-ﬂanked (ﬂoxed) Pparg allele and an
Fabp4-driven fusion of Cre with a tamoxifen-responsive es-
trogen receptor mutant, which translocates to the adipocyte
nucleus and targets the ﬂoxed allele only in response to ta-
moxifen administration. Induction of Cre activity in these
mice induced synchronous, near-complete loss of white and
brown adipocytes within 7 days, followed by acute inﬂam-
matory inﬁltration of the damaged fat pads, and complete
rebound of adipocyte number and adipose tissue integrity
within 6 weeks of the initial insult [33]. Thus, PPARγ is es-
sential for the survival of mature adipocytes, but a rapid and
robust regenerative process mitigates a loss of fat tissue fol-
lowing Pparg deletion. Similar regenerative potential of adi-
posetissuewasrecentlydemonstratedinmicewithinducible
adipocyte apoptosis [46], buttressing the notion that fat re-
generateswithremarkableeﬃciencyinresponsetoadipocyte
death, beyond the context of PPARγ deﬁciency. Thus, adi-
pose tissue of Fabp4-Cre Ppargﬂ/ﬂ mice comprised a dynamic
mixture of dying Pparg-null adipocytes alongside repopu-
lating wt adipocytes—a condition that hindered the genera-
tion of mice with adipose tissue that uniformly lacks PPARγ.
As long as WAT was sustained, these mice maintained rel-
atively normal lipid and glucose homeostasis, despite sub-
stantial reduction in circulating leptin and adiponectin and
an anticipated rise in the levels of free FA [32, 45]. Mod-
erate IR and glucose intolerance, as well as hepatomegaly,
steatosis, and increased hepatic glucose production, devel-
oped only in conjunction with the eventual terminal atro-
phy of WAT [32]. Analyses of two independent stocks of
these mice by two researchteams found obvious resistance to4 PPAR Research
HFD-induced obesity, likely due to the failure to accumulate
adipocytes.However,thetwoteamsobservedoppositeeﬀects
oninsulinsensitivity.Inonestudy,HFDacceleratedlipoatro-
p h ya n de x a c e r b a t e dI R[ 32], whereas the other study found
no such degenerative eﬀect and the mutation protected the
mice from IR [45]. In summary, while reproving the critical
role of WAT in systemic insulin sensitivity and the indispens-
ability of PPARγ toadipocyte viability,the adipocyte-speciﬁc
Pparg-null mouse fell short of a deﬁnitive demonstration
that adipocyte PPARγ regulates whole body metabolism.
2.2.2. Myocyte-speciﬁcPpargKO
The insulin sensitizing activity of PPARγ ligands and the
key role of skeletal muscle in peripheral insulin sensitivity
generated great interest in the hypothesis that PPARγ exerts
its insulin sensitizing activity from within myocytes. How-
ever, this hypothesis was challenged by the very low basal
expression of PPARγ in skeletal muscle. The issue was ad-
dressed by two parallel studies that analyzed the outcome
of Pparg deletion in myocytes. In the ﬁrst study, myocyte-
speciﬁcPparg-nullmicegeneratedbyMCK promoter-driven
Cre recombinase exhibited increased adiposity, elevated sus-
ceptibility to HFD-induced weight gain, and marked hep-
atic IR in hyperinsulinemic-euglycemic clamps [47]. How-
ever, these mice were only as sensitive to HFD-induced IR
and as responsive to the insulin sensitizing eﬀects of TZDs as
wt mice, suggesting that muscle PPARγ is dispensable for the
antidiabeticeﬀectsofPPARγ agonists.Thesecondstudyused
mice generated using the same Cre transgene, but a diﬀer-
ent ﬂoxed Pparg allele, and ﬁrst addressed the controversial
issue of low PPARγ expression in myocytes [48]. It demon-
strated that the minute amount of Pparg mRNA observed in
muscle extracts undergoes MCK-Cre-mediated recombina-
tion, and thus, unequivocally proved that the transcript orig-
inated in myocytes rather than other cell types that popu-
late muscle tissue. Mice in this study developed insulin and
glucose intolerance with age, and exhibited severely com-
promised insulin-stimulated muscle glucose uptake, as well
as liver and adipose tissue IR. In contrast to the ﬁrst study,
hereTZDsfailedtoamelioratemuscleinsulinresistance,sug-
gesting that myocyte PPARγ regulates muscle insulin sensi-
tivity cell autonomously. While the diﬀerential sensitivity of
the two strains to TZDs raises concerns about the validity
of the interpretations, they are not necessarily contradictory,
considering that both the metabolic challenges (HFD ver-
sus aging) and the assayed activities (Insulin tolerance tests
versus muscle glucose uptake) were diﬀerent in each study.
Still, more deﬁnitive studies, using mice with a purer genetic
background and a standardized experimental approach, are
required to settle these discrepancies. Regardless of the ﬁnal
answer,itisclearthatwhilePPARγ mayhavesomemetabolic
functionsinmyocytes,thesefunctionsarenotsuﬃcientlyro-
busttoaccountforthesystemicantidiabeticactionsofTZDs.
2.2.3. Hepatocyte-speciﬁcPpargKO
As in muscle, basal PPARγ expression in liver is minimal.
However, hepatic PPARγ expression is induced substantially
during steatosis. The eﬀects of albumin Cre-mediated hepa-
tocyte Pparg deﬁciency were studied in wt and two diﬀerent
diabetic mouse models that succumb to steatosis—A-Zip/F
lipoatrophic mice and leptin-deﬁcient ob/ob mice [49, 50].
On an otherwise wt background, hepatic Pparg deﬁciency
caused a signiﬁcant defect in TG clearance, hyperlipidemia,
and increased body fat mass with age, demonstrating the im-
portance of hepatic PPARγ for basal fat tolerance and man-
agement of adiposity [50]. On the two diabetic backgrounds
deﬁciency of hepatocytes for Pparg caused marked ameliora-
tion of hepatosteatosis, but exacerbated hyperlipidemia and
muscle insulin resistance [49, 50] .T h e s et r a i t sw e r er e v e r s e d
by TZDs in ob/ob, but not A-Zip/F mice, suggesting that
the drugs exert their eﬀect through activation of PPARγ in
adipocytes, not hepatocytes. Together, these studies indicate
thathepatocytePPARγ isrequiredforbasalfattoleranceand,
in addition, for steatosis of the diabetic liver, which serves to
improve TG homeostasis and dampen systemic IR. However,
they also clearly indicate that hepatic PPARγ is not critical
for TZD-induced insulin sensitization.
2.2.4. Othertissue-speciﬁcPpargKOs
The relatively modest eﬀects of PPARγ deﬁciencies in fat,
muscle, and liver provided the impetus for broadening the
analysis of Pparg KO to additional cell types that partici-
pate in obesity-associated metabolic complications, namely
diabetes, hypertension, and atherosclerosis. The outcomes of
these analyses are brieﬂy summarized as follows.
Pparg deﬁciency in β-islets caused a hyperplastic re-
sponse without altering glucose homeostasis, ruling out a
critical function of the receptor in homeostatic functions of
β cells [51].
A strong rationale for the generation and analysis
of Pparg- n u l lm a c r o p h a g e sw a sp r o v i d e db yo b s e r v a t i o n s
that TZDs induce macrophage genes that regulate lipid
ﬂux, suppress inﬂammatory gene expression, and amelio-
rate atherosclerosis [52–54]. Early studies with Pparg-null
macrophages in culture and in vivo demonstrated that TZD
eﬀectsonlipoproteinﬂuxindeeddependonPPARγ,butsev-
eralofthereportedanti-inﬂammatoryeﬀectsofTZDsarein-
dependent of PPARγ [44, 55]. Nevertheless, adaptive trans-
fer of Pparg-deﬁcient macrophages exacerbated genetic- and
diet-induced atherosclerosis in recipient mice, demonstrat-
ing that PPARγ performs key anti-atherogenic functions in
these cells [56, 57]. In addition, a recent, yet-to-be-published
symposium talk reported that macrophage-speciﬁc Pparg-
null mice are glucose intolerant and exhibit increased sensi-
tivity to HFD-induced insulin resistance [58]. Thus, PPARγ
orchestrates multiple beneﬁcial activities in macrophages
that could be harnessed for the development of advanced
therapies for atherosclerosis.
Edema due to ﬂuid retention is an undesired side eﬀect
of TZD treatment in diabetic patients [59]. Mice with Pparg
KO in renal collecting duct epithelia are resistant to this
TZD-borne complication, conﬁrming that PPARγ mediates
it, apparently by enhancing sodium retention [60, 61]. This
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PPARγ may regulate plasma volume, hypertension, and car-
diovascular function.
Pparg deletioninendothelialcellsexacerbatesbothHFD-
inducedandsalt-inducedhypertension,andrendersthecon-
dition nonresponsive to TZDs, demonstrating that endothe-
lialPPARγ iscriticalformitigatingtheeﬀectsofdietarystress
on blood pressure [62].
Ablation of PPARγ in cardiomyocytes causes elevated
cardiac NF-κB activity and increased expression of cardiac
embryonic genes, which lead to enhanced myoﬁbril assem-
blyandcardiachypertrophybutdoesnotaﬀectsystolicfunc-
tion [63]. The relationship between this phenotype and the
metabolic functions of PPARγ in other tissues is not entirely
clear, although aspects of cardiac lipid metabolism have yet
to be addressed in this mouse.
2.3. Pparg2-speciﬁcKOs
Alternative promoters give rise to several Pparg isoforms
with distinct 5  ends. PPARγ1 is the ubiquitous isoform, ex-
pressed in all PPARγ-expressing tissues [64]. Adipocytes ex-
press, in addition to PPARγ1, a cell-speciﬁc isoform termed
PPARγ2, whose unique 5  exon encodes a 30 residue-long N-
terminalextensionoftheligand-independenttransactivation
domain of PPARγ1[ 65]. Because the placenta expresses only
PPARγ1, KO of PPARγ2 could provide yet another means to
bypass the lethal outcome of constitutive Pparg deﬁciency,
as well as to interrogate potential unique functions of this
adipocyte-speciﬁc isoform. In all, three teams have knocked
out Pparg2 using distinct targeting strategies that produced
slightly diﬀerent results [66–68]. Knock-in of red ﬂuores-
cent protein into the Pparg2-speciﬁc B exon produced a
clean KO of PPARγ2 while retaining normal PPARγ1e x p r e s -
sion in adipocytes [66]. This conﬁguration interfered with
adipocyte diﬀerentiation in vitro and markedly reduced fat
mass in vivo. This lipodystrophic phenotype involved sig-
niﬁcant reduction in the size, number, and TG content of
brown and white adipocytes, and decreased expression of
typical adipocyte markers [66]. A second knockout conﬁg-
uration entailed replacement of the entire B exon and ﬂank-
ing intronic sequences with a lacZ-neo cassette and resulted
in a similar Pparg2-speciﬁc gene disruption, without aﬀect-
ing Pparg1 [67]. This conﬁguration was as detrimental to
adipocyte diﬀerentiation in vitro as the previous KO con-
ﬁguration, but unlike that KO it had only a marginal eﬀect
on either fat mass or basal adipocyte size [67]. It is unclear
whetherthesediﬀerencesaremeaningfulorratherreﬂectmi-
nor diﬀerences in the experimental setup used by the two
teams, for example in allele conﬁguration, the genetic back-
ground of the mice, composition of the chow, or analyti-
cal methods. A third Pparg2 targeting conﬁguration, which
resulted from an intronic neo cassette downstream of exon
B, eliminated Pparg2 expression but inadvertently altered
Pparg1 expression, abolishing it in WAT while augmenting
it in BAT [68]. Mice homozygous for this modiﬁcation were
deemed PPARγ hypomorphs (Pparghyp/hyp). Unlike the ﬁrst
two conﬁgurations, Pparghyp/hyp were subject to high mor-
tality rate and growth retardation during infancy; survivors
thrived after weaning but were substantially lipodystrophic
[68].Importantly,contrarytoothermodelsoflipodystrophy,
all three Pparg2-null conﬁgurations, including Pparghyp/hyp,
exhibited a surprisingly modest decrease in glucose or in-
sulin tolerance and did not develop steatosis. The suggestion
that this relatively healthy phenotype is mitigated by com-
pensatory lipid oxidation in muscle tissue [68]h a st ob er e c -
onciled with the failure of a similar compensatory mecha-
nism to oﬀset other cases of lipodystrophy.
2.4. Knock-inofdominant-negativemutations
fromhumanpatients
As if the analyses described to this point were not suﬃ-
ciently counterintuitive and indecisive, mice heterozygous
for Pparg-L466A or Pparg-P465L—two dominant-negative
missense mutations identiﬁed in human subjects—provided
further surprises. Patients carrying one allele of either muta-
tion alongside a second wt allele suﬀer from partial congeni-
tal lipodystrophy with hallmarks of the metabolic syndrome,
including dyslipidemia, early-onset type II diabetes, and hy-
pertension[69–73].Itthereforemadeperfectsensetoreplace
the mouse Pparg gene with similar mutations, with the obvi-
ousexpectationofrecapitulatingtheclinicalphenotype.Two
research teams carried out this endeavor, each knocking in
one of the mutations [74, 75]. Mice homozygous for either
mutation died in utero, demonstrating the null nature of the
alleles. However, while mice heterozygous for either muta-
tion exhibited moderate hypertension and anomalies of ei-
ther fat distribution or adipocyte morphology, none fully re-
capitulated the lipodystrophic phenotype of the orthologous
patients [74, 75]. Moreover, PpargP465L/+ mice displayed no
gross changes in plasma chemistry and were in fact more
glucose tolerant than wt mice, both basally and following
HFD, just like standard Pparg-haploinsuﬃcient mice [74].
In addition, although more physiological anomalies were
reported for PpargL466A/+ mice compared to PpargP465L/+
mice, including elevated free FA levels, hepatic steatosis and
HFD-inducedinsulinresistance[75],theirmorbiditydidnot
amount to that of their human counterparts.
2.5. OthergeneticmanipulationsofPparg
In addition to the Pparg KO onslaught, there has been a sub-
stantial public health interest in more subtle aspects of its
function.Theseinclude theeﬀectsof genetic polymorphisms
andpost-translationalmodiﬁcations,whichhavebeenlinked
both genetically and epidemiologically to obesity and type
II diabetes in the human population [76–79]. The ﬁrst re-
ported eﬀort that undertook this approach is the S112A
point mutation, which eliminates a MAP kinase phosphory-
lation site that inhibits the transcriptional activation capac-
ity and adipogenic functions of PPARγ [80]. PpargS112A/S112A
mice are viable and healthy, and do not display physiolog-
ical anomalies under normal husbandry. However, the fail-
ure to regulate PPARγ action by phosphorylation protects
these mice against HFD-induced adipocyte hypertrophy and
insulin resistance [80]. These results validate the utility of6 PPAR Research
subtle structural mutations for uncovering important physi-
ological activities of PPARγ. Informal communications with
other researchers, as well as the public NIH grant database,
reveal that additional genetic manipulations aimed at under-
standing the biological function of conserved and polymor-
phic sequence elements of PPARγ are currently underway in
mice.
2.6. PpargKOs—summaryandremarks
Inaggregate,aslewofattemptstogeneratemoleculargenetic
models that will reveal a role for PPARγ in obesity, insulin
resistance, and related metabolic disorders have yielded par-
tial success and confounding results. Constitutive Pparg KO
was nonviable, Pparg haploinsuﬃciency was unexpectedly
beneﬁcial, and the pathogenic eﬀect of dominant-negative
Pparg mutations in human patients was not faithfully repli-
cated in mouse models. Reassuringly, chimeric mouse stud-
iesandadipocyte-speciﬁcKOsunequivocallyprovedthecrit-
ical role of PPARγ in adipocyte diﬀerentiation and survival.
However, the potential for an interpretable eﬀect on energy
metabolism was thwarted by the inability to obtain long-
lasting Pparg-null adipocytes, which did not allow teasing
out the eﬀect of PPARγ deﬁciency from the general impact
of lipodystrophy. Quite disappointingly, KOs in other tissues
had relatively modest eﬀects basally and latent metabolic de-
fects in response to dietary or genetic challenges. While these
studies invoked encouraging links to atherosclerosis and hy-
pertension, none amounted to full-blown IR, let alone dia-
betes. These major deviations from straightforward expecta-
tions raise concerns about the applicability of genetic stud-
ies of Pparg in the mouse to human metabolism. However,
one should be reminded that TZDs are equally potent as in-
sulin sensitizers in both mice and humans [35, 36], highly
suggestive of similar metabolic functions of PPARγ per se
across species. A more likely explanation for the relatively
benign outcomes of these studies is the inherently ﬁckle na-
ture of genetic, physiological, and metabolic experiments in
mice. Evolution likely diﬀerentiated metabolic physiology in
rodents versus humans, and although PPARγ may have the
exact same function in the bigger scheme, other genes and
pathways may modify the outcome. In addition, lab mice
are reared in a highly controlled ambient and provided ei-
ther with uniform lean chow that diﬀers drastically from hu-
man diet, or with experimental diets that mimic our own di-
etary follies, but which rodents have not evolved to handle.
Eﬀects of genetic background and modiﬁer genes on out-
comes and their interpretation comprise another obstacle.
On the one hand, many of the studies summarized here do
not clarify the extent of genetic homogeneity of the tested
cohorts, potentially obstructing minor, yet critical eﬀects of
the mutations. On the other hand, the human population
is genetically diverse, and gene defects that would devastate
one person could be inconsequential in another. A case in
point is the dramatic exacerbating eﬀe c to fam u t a t i o ni n
the PPP1R3A gene on the outcome of PPARG mutations in
a human pedigree [72]. Genes and pathways with compa-
rable modifying eﬀects could compensate for the eﬀects of
Pparg deﬁciency in mice. Moreover, redundant activities of
PPARγ in diﬀerent tissues or an altogether misguided choice
oftargettissuesandreadoutsmighthavefurtherhinderedin-
terpretation. Finally, it may be time to start entertaining the
notion that the problem might be with the hypothesis itself:
clearly, activation of PPARγ with TZDs is a robust therapy
for IR, but does this mean that the pathway is necessary for
basal insulin sensitivity in mice and men?
3. PPARδ
PPARδ was initially regarded as a promising prospect for
studies of obesity and associated diseases purely on the
merit of its pharmaceutically accomplished homologues
[64]. With pharmacological agonists and genetic manipula-
tions of PPARδ coming to fruition in recent years, these ex-
pectations are starting to be realized, and implicate PPARδ
in important aspects of obesity, energy metabolism and
metabolic disease. As in Pparg-null mice, analysis of Ppard
deﬁciency also faces the challenge of substantial embryonic
mortality, albeit for completely diﬀerent reasons. The na-
ture of the challenge, the diﬀerent solutions, and the associ-
ated caveats are discussed brieﬂy as a primer to the review of
phenotypes associated with Ppard-null and gain-of-function
models.
In all, 6 Ppard-null conﬁgurations have been generated
inmice.Threeknockoutstrainsharboringdeletionsorinser-
tions that wipe out the PPARδ protein product in its entirety
cause severe placental defects that lead to substantial embry-
onicmortality[81–83].Whiletherearepracticallynosurviv-
ing homozygous null animals on the standard, C57BL/6 (B6)
background,survivalisincreasedtobetween5%and20%on
outbred B6 : 129/Sv [81] or FVB : B6 backgrounds (Y. Barak,
unpublished data). Unfortunately, Ppard- n u l lm i c ea n dwt
controls generated in this fashion inherently possess mixed
genetic backgrounds, whose stochastic quantitative trait lo-
cus eﬀects signiﬁcantly muddle physiological data. In addi-
tion, through successive interbreeding of surviving homozy-
gous null FVB : B6 mice over several generations, our lab
has managed to generate a genetically semistable Ppard-null
stock with approximately 50% survival (Y. Barak, unpub-
lisheddata).However,whilethisstockprovidesahigheryield
of Ppard-null mice with a relatively isogenic background, the
natureofthebreedingstrategyhinderedthegenerationofge-
netically matching wt controls. In a fourth Ppard null allele,
no substantial embryonic lethality was reported [84]. How-
ever, in this allele Ppard was truncated 60 amino acids from
its C-terminus, leaving its entire DNA-binding domain and
most of its ligand-binding domain intact, and raising a rea-
sonable concern that it is a hypomorph that enabled embry-
onic survival via residual PPARδ functions. Therefore, anal-
yses of adult mice carrying this KO conﬁguration have to
be interpreted with the cautionary note that it is likely in-
completely deﬁcient for PPARδ. Finally, ﬂoxed Ppard alleles
have been generated as well [81, 85]. These conﬁgurations
enablethetargetingofPpard inspeciﬁctissueswiththeobvi-
ous caveat that Cre-mediated deletion of ﬂoxed alleles is sel-
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mice is used in the following text to describe animals with
germ-line deletion of the gene in all tissues, whereas studies
performed with tissue-speciﬁc Ppard KOs are spelled out.
3.1. GeneticmanipulationsofPPARδ
andadiposetissue
Early studies of outbred Ppard-null mice under standard
husbandry conditions revealed a substantial decrease in the
size of BAT and WAT [81, 84]. Fat mass was not reduced in
adipocyte-speciﬁc Ppard- n u l lm i c e( ﬂ o x e dPpard x Fabp4-
Cre)[ 81], demonstrating that this trait is not adipocyte-
autonomous, and must result from impaired PPARδ activity
inothertissues.Whileunabletoachievenormaladiposity on
standard,lowfatchow,Ppard-nullmiceunderwentaquicker
and substantially more aggressive weight gain in response to
HFD compared to wt controls [86, 87]. These observations
were complemented and extended by studies of mice ex-
pressingconstitutivelyactivePPARδ inadiposetissue[87].In
these mice, the Fabp4 promoter drives adipocyte-speciﬁc ex-
pression of a fusion protein between the transactivation do-
main of the Herpes Virus VP16 protein and PPARδ (Fabp4-
VP-Ppard), such that the latter is rendered permanently ac-
tive, irrespective of endogenous ligands. When reared on
standard, low-fat chow Fabp4-VP-Ppard mice exhibited sig-
niﬁcantreductioninbodyweightandintheoverallmassand
TG content of adipose tissue, as well as in the levels of cir-
culating TG and free FA [87]. However, the mice were pro-
tected from the adipocyte hypertrophy, dyslipidemia, obe-
sity, and steatosis that occur in response to either HFD or
impaired leptin signaling [87]. Quelling of obesity in these
mice was associated with upregulation of genes that control
lipid catabolism and adaptive thermogenesis in both BAT
and WAT; reassuringly, the same genes are induced in re-
sponse to systemic administration of a PPARδ ligand [87].
In contrast, adipocyte-speciﬁc PPARδ deﬁciency compro-
mised HFD-mediated induction of the uncoupling protein
1g e n e ,Ucp1,i nB A T[ 87]. Combined, these two genetic ex-
tremes of deﬁciency versus constitutive activation identify
PPARδ as a critical regulator of lipid homeostasis and adi-
posity.
3.2. GeneticmanipulationsofPPARδ andmuscle
The abundant expression of PPARδ in myocytes suggests an
i m p o r t a n tr o l ei ns k e l e t a lm u s c l e[ 2]. Two transgenic models
of muscle-speciﬁc PPARδ overexpression and one of muscle-
speciﬁc Ppard-deﬁciency conﬁrmed this notion and revealed
amassiveimpactofPPARδ onmuscleandwholebodyphysi-
ology.MCKpromoter-drivenexpressionofconstitutivelyac-
tive VP-Ppard resulted in a dramatic type switch of muscle
from type II, glycolytic ﬁbers to type I, slow-twitch, oxida-
tive ﬁbers, and a staggering increase in aerobic endurance
[88]. This switch was associated with activation of the typical
oxidative ﬁber expression program, including genes that reg-
ulate lipid catabolism, mitochondrial electron transfer, ox-
idative metabolism, and type I contractile structures [88].
Overexpression of wt Ppard in skeletal muscle activates a
similar expression pattern, and falls just short of inducing
ﬁber-type switching [89]; the tamer induction of these genes
in the latter mouse strain reﬂects the lesser activity of wt
PPARδ compared to the VP16-fused variant. These obser-
vations were fully corroborated by skeletal muscle-speciﬁc
KO of Ppard, which resulted in the reciprocal muscle type
switch from high- to low-oxidative ﬁbers [85]. Molecular
analyses of these mice revealed that PPARδ regulates the ex-
pression of the transcriptional cofactor PGC1α, which regu-
lates mitochondrial biogenesis and muscle type switch, pro-
viding a plausible mechanistic explanation for the basis of
PPARδ function in muscle [85]. Remarkably, constitutive ac-
tivity of PPARδ in muscle protected the mice from HFD-
inducedadipocytehypertrophy,obesity,andIR,demonstrat-
ingthemajorinﬂuenceofPPARδ-inducedenergydissipation
in muscle on systemic energy homeostasis [88]. In full agree-
ment with these ﬁndings, muscle-speciﬁc Ppard deﬁciency
resulted in obesity, adipocyte hypertrophy, and insulin re-
sistance [85]. Moreover, the basal respiratory quotient and
glucose tolerance of whole-body Ppard-null mice are signif-
icantly reduced in the absence of additional dietary or ge-
netic challenges [90]. Combined, these observations indicate
that enhancement of basal metabolism by PPARδ in general,
a n di nm u s c l ei np a r t i c u l a r ,a r ec r i t i c a lf o rs y s t e m i ce n e r g y
homeostasis, and play a pivotal role in curbing obesity and
its metabolic sequelae.
In addition to the gain and loss-of-function studies in
skeletal muscle, loss-of-function studies revealed a critical
requirement for PPARδ also in cardiac muscle. Cardiomyo-
cyte-speciﬁc Ppard- n u l lm i c e( ﬂ o x e dPpard x MHC-Cre)e x -
hibited reduced expression of genes regulating FA oxida-
tion, accompanied by progressive cardiac lipid accumula-
tion, cardiac hypertrophy, and dilated cardiomyopathy [91].
The mice develop typical symptoms of congestive heart fail-
ure and died within the ﬁrst 10 months of life, demonstrat-
ing the vital importance of PPARδ for myocardial FA ox-
idation and function [91]. Considering that mice carrying
germ-line Ppard deﬁciency reach old age without major in-
cident [81, 85], the harsher phenotype of mice that lack this
PPAR only in the heart requires explanation. In addition, as
PPARα induces similar pathways of cardiac FA oxidation and
protection from lipotoxicity (see above), it will be crucial to
determine how these diﬀer from those regulated by PPARδ,
and why neither PPAR compensates for the deﬁciency of the
other.
3.3. GeneticmanipulationsofPPARδ
andatherosclerosis
The abundant expression of PPARδ in macrophages pro-
vided a compelling rationale to study its contribution to
macrophage biology and atherosclerosis. Comparative stud-
ies of wt versus Ppard-null embryonic stem cell-derived
macrophagesidentiﬁedverylow-densitylipoprotein(VLDL)
as a rich source of PPARδ agonists and the gene for the
lipid droplet-associated ADRP protein as a tightly regu-
lated PPARδ target gene [82]. Combined with the observed8 PPAR Research
increasesinhepaticVLDLproduction,circulatingVLDLlev-
els, and VLDL-associated TG in Ppard-null mice [86], this
functional interaction suggested that PPARδ is engaged in
negative feedback regulation of systemic VLDL ﬂux. While
these studies provide circumstantial support for the poten-
tial role of PPARδ in macrophage lipid metabolism, subse-
quent studies found no eﬀect of PPARδ deletion or activa-
tion on cholesterol ﬂux in macrophages [92]. In contrast,
deletion of the Ppard gene reduced the expression of pro-
inﬂammatory genes in macrophages, as did treatment with
PPARδ agonists [92]. The similar eﬀects of PPARδ deﬁciency
and activation invoke a mechanism, in which the associ-
ation of unliganded PPARδ with transcriptional corepres-
sors promotes inﬂammation, which can be relieved by either
ligand-mediated derepression or an outright gene KO. Most
importantly, these activities have a measurable impact on
atherosclerosis, and transplantation of Ppard-null bone mar-
row markedly suppressed atherosclerosis in LDL-receptor
KO mice [92]. Thus, basal PPARδ activity in macrophages
augmentsthepathogenesisofatherosclerosis,andPPARδ lig-
ands may exert therapeutic eﬀects by reversing, rather than
enhancing, this pathogenic activity.
4. SUMMARY AND PROSPECTS
This review summarized the insights obtained into the func-
tions of PPARs in obesity and metabolic disease through ge-
netic manipulation of mice. For focus purposes, we excluded
manyofthestudiesthatprovidedseminalinsightsintothein
vivo functions of PPARs through the use of pharmacological
agents; this information is available in other reviews in this
volume and elsewhere.
Itisevidentfromthestudiesreviewedthatdeﬁcienciesor
unscheduled expression of PPARα,P P A R γ,a n dP P A R δ im-
pact multiple tissues and vital metabolic processes, and that
despite their substantial homology and evidence of shared
transcriptional targets, the physiological functions of each
are unique. These observations are compiled in Figure 1.
Some of the conclusions that emerge from these stud-
ies are consistent and irrefutable, such as the critical role
of PPARα in the fasting response, the indispensability of
PPARγ for adipocyte diﬀerentiation and survival, or the role
of muscle PPARδ in ﬁber type determination and basal ox-
idative metabolism. Other conclusions are solid, but could
be reﬁned and extended by further studies; examples include
the antiatherosclerotic functions of PPARγ.H o w e v e r ,m a n y
studies report data and conclusions that seem either over-
stated or in conﬂict altogether with other studies. Neverthe-
less, in case of studies in the latter category we tried our best
tosummarizethedataaspublished,pointoutmajordiscrep-
ancies, and where possible, provide plausible explanations
for disparities between reports, while leaving it to the readers
to formulate their own judgment. Still, the text is likely per-
meated with some of our own biases, formed through infor-
mal discussions with other researchers, familiarity with the
evolution of some of the concepts and hypotheses, and our
own unpublished work.
Aspointed outthroughoutthis review,inconsistencies or
erroneous data could readily arise from minor imperfections
in the targeting strategy, inappropriate heterogeneity of the
genetic background, diﬀerences in husbandry, feeding regi-
mens and experimental protocols, and, last but not least, hu-
man error. Although these issues need to be ironed out in the
long term, one may take the philosophical stance that hard-
to-reproduce results are too minor to be biologically signiﬁ-
cant. This leaves us with the larger, yet-to-be-answered ques-
tions that should be addressed by genetic manipulations of
PPARs in the near future.
CurrentlyoneofthebiggestquestionsconcerningPPARα
is the therapeutic promise of ﬁbrate drugs and derivatives,
which have been all but neglected in recent years. Consider-
ing the unique functions of PPARα in lipid clearance and the
fasting response, are there adverse metabolic conditions for
which the potential of its agonists to provide an ideal treat-
ment has been overlooked? The combined eﬀects of Ppara
KO and agonists on animal models of various diseases that
entail altered lipid homeostasis should provide answers to
this question.
For PPARγ, several mysteries beg resolution, none more
important than its connection to insulin sensitization, which
has thus far eluded deﬁnitive proof. The following are three
examples for the many potential approaches that could
be employed to address this topical issue. First, beyond
its importance for adipogenesis and adipocyte viability, is
adipocyte PPARγ a major player in systemic metabolism?
Can we gain a molecular understanding of the death mech-
anism of Pparg-null adipocytes and use it to delete Pparg
in these cells while averting their death? Assuming that we
can devise such methods to obtain mice with viable Pparg-
null adipocytes, what would their metabolic phenotype be?
Second, we should continue to explore the contributions of
PPARγ to metabolic homeostasis through its actions in ad-
ditional tissues. Considering the critical role of central reg-
ulation in energy homeostasis, one glaringly neglected hy-
pothesis is that PPARγ may also function centrally; this idea
could be tested by tissue-speciﬁc Pparg KOs in the CNS and
hypothalamic neurons. Third, we do not yet understand the
mechanisms of insulin sensitization by Pparg haploinsuﬃ-
ciency. Additional in vivo experiments are required to iden-
tify the culprit tissue(s) and the target genes whose deregula-
tion underlies this phenomenon.
PPARδ research has been lagging behind that of PPARα
and PPARγ, and new ﬁndings are starting to trickle from
multiple tissue-speciﬁc Ppard KOs. The immediate sig-
niﬁcant questions revolve around the detailed mechanis-
tic understanding of PPARδ action in lipid and oxidative
metabolism and in inﬂammation. Considering that Ppard-
null mice surviving gestation are by and large healthy under
standard husbandry, how important are these functions for
basalhealth?Andwhenthesefunctionscomeintoplayunder
metabolicstress,howcantheybemodulatedforthebestpos-
sible treatment of metabolic diseases? As pointed out above,
combination studies of pharmacological agonists and genet-
ically manipulated animals will bring us several steps closer
to answering these questions.Y. Barak and S. Kim 9
Endothelial cells
Pparg-null: diet-induced hypertension;
refractory to TZDs
Macrophages/atherosclerosis
Pparg-null: impaired cholesterol eﬄux;
worsened atherosclerosis
Ppard-null: reduced inﬂammation;
improved atherosclerosis
β-cells
Pparg-null: β-islet hyperplasia;
normal glucose homeostasis
Kidney
Pparg-null: reduced sodium absorption;
resistance to TZD-induced edema
Placenta
Pparg-null: failed development;
embryonic lethality
Ppard-null: fragile decidual barrier;
strain-dependent death
Heart
Ppara-null: lipid accumulation;
lipotoxicity
Pparg-null: cardiac hypertrophy
Ppard-null: lipid accumulation;
hypertrophy;
dilated cardiomyopathy
Liver
Ppara-null: no response to PPs;
hyperlipidemia & steatosis;
impaired fasting resopnse
Pparg-null: fat intolerance;
in diabetic mice:
ameliorates steatosis;
increased IR
Adipose tissue
Ppara-null: mass gain with aging;
shrinkage on high-cholesterol diet
Pparg-null: failed adipogenesis;
adipocyte death; lipodystrophy
Ppard-null: reduced adiposity;
increased mass gain on HFD
VP-Ppard Tg: reduced adiposity;
protection from obesity
Skeletal muscle
Pparg-null: latent IR
VP-Ppard Tg: increased type I ﬁbers:
elevated endurance;
protection from obesity
Ppard-null: reduced type I ﬁbers;
obesity; IR
Figure 1:GeneticmanipulationsofPPARs—compilationofmetabolicphenotypes.Theschemesynthesizesobservationsfrombothwhole-body
and tissue-speciﬁc KOs.
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